{'fraction_non_alphanumeric': 0.062022090059473234, 'fraction_numerical': 0.052676295666949875, 'mean_word_length': 4.428571428571429, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Management of acute ischemic stroke under routine infection prevention practices for COVID-19

We greatly appreciate the comments made by Leslie-Mazwi et al .1 As they mentioned, the lack of a 90-day modified Rankin Scale (mRS) was a major limitation of our study. In order to share our first-hand experience as soon as possible during the pandemic, we only reported 7- day outcomes. However, the 90-day follow-up was pre-planned, as we stated in response to peer review comments. As shown in figure 1, a good clinical outcome (mRS ≤2) was seen in 52.9% (9/17) in the pandemic group compared with 39.4% (13/33) in the pre-pandemic group; this difference was not statistically significant (p=0.361). No significant difference was identified for either 90-day mortality (4/17 (23.5%) vs 5/33 (15.2%), p=0.732) or 90-day National Institutes of Health Stroke Scale score (4, IQR 1–12 vs 8, IQR 4–10; p=0.320) in the pandemic and pre-pandemic groups, respectively. However, the small sample size may partially account for this equivalence, therefore future prospective multicenter studies are warranted.



Figure 1 
Distribution of functional outcomes at 90 days. Modified Rankin …